Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088870 | 1.00 | KCNH2 (0.41) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL21845242 | 0.86 | PTPN11 (0.39) | KCNH2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21887248 | 0.83 | CYP2D6 (0.40) | KCNH2KDM1APTPN11 | |
| SCHEMBL22393722 | 0.83 | CYP2D6 (0.40) | KCNH2KDM1APTPN11 | |
| SCHEMBL21887220 | 0.81 | PTPN11 (0.46) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL21887223 | 0.80 | GRIN2D (0.49) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL21887296 | 0.79 | GRIN2D (0.37) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24089033 | 0.79 | GRIN2D (0.37) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24088920 | 0.74 | GRIN2D (0.36) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL21887227 | 0.74 | GRIN2D (0.36) | KCNH2GRIN2DGRIN3BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | KCNH2 4269/4885GRIN2D 3730/4885GRIN3B 3231/4885 |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | KCNH2 4269/4885GRIN2D 3730/4885GRIN3B 3231/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | KCNH2 4293/4885GRIN2D 3602/4885GRIN3B 3133/4885 |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPN2 | KCNH2 4546/4885GRIN2D 3510/4885GRIN3B 2830/4885 |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | KCNH2 4269/4885GRIN2D 3730/4885GRIN3B 3231/4885 |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | KCNH2 4269/4885GRIN2D 3730/4885GRIN3B 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.